Known targets — ChEMBL curated mechanism
The experimentally established mechanism targets of Meprednisone. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NR3C1 known ✓ | P04150 | 6/20 | 0.70 |
| ▸ | HSD17B10 | Q99714 | 6/20 | 0.70 |
| ▸ | HIF1A | Q16665 | 6/20 | 0.70 |
| ▸ | PGR | P06401 | 5/20 | 0.70 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.70 |
| ▸ | LMNA | P02545 | 3/20 | 0.70 |
| ▸ | MEN1 | O00255 | 2/20 | 0.70 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.70 |
| ▸ | SLC29A1 | Q99808 | 1/20 | 0.70 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.70 |
| ▸ | FNTA | P49354 | 1/20 | 0.57 |
| ▸ | FNTB | P49356 | 1/20 | 0.57 |
| ▸ | NFKB1 | P19838 | 4/20 | 0.55 |
| ▸ | NFKB2 | Q00653 | 2/20 | 0.55 |
| ▸ | RELA | Q04206 | 2/20 | 0.55 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.55 |
| ▸ | CYP3A4 | P08684 | 6/20 | 0.54 |
| ▸ | AR | P10275 | 3/20 | 0.54 |
| ▸ | TSHR | P16473 | 2/20 | 0.54 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.54 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Meprednisone SCHEMBL20856991 | 1.00 | HSD17B10 (0.70) | HSD17B10NR3C1HIF1APGRKMT2A | |
| Meprednisone SCHEMBL9512 | 1.00 | HSD17B10 (0.70) | HSD17B10NR3C1HIF1APGRKMT2A | |
| Meprednisone SCHEMBL19327148 | 1.00 | HSD17B10 (0.70) | HSD17B10NR3C1HIF1APGRKMT2A | |
| Meprednisone SCHEMBL11846862 | 1.00 | HSD17B10 (0.70) | HSD17B10NR3C1HIF1APGRKMT2A | |
| Meprednisone SCHEMBL16759699 | 0.93 | HSD17B10 (0.83) | HSD17B10NR3C1HIF1APGRKMT2A | |
| SCHEMBL25932838 | 0.91 | NR3C1 (0.60) | HSD17B10NR3C1HIF1APGRKMT2A | |
| SCHEMBL7611011 | 0.89 | FNTA (0.60) | HSD17B10NR3C1HIF1APGRKMT2A | |
| SCHEMBL11038018 | 0.88 | KMT2A (0.72) | HSD17B10NR3C1HIF1APGRKMT2A | |
| SCHEMBL11038901 | 0.88 | KMT2A (0.72) | HSD17B10NR3C1HIF1APGRKMT2A | |
| SCHEMBL11038015 | 0.88 | KMT2A (0.72) | HSD17B10NR3C1HIF1APGRKMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20070021360-A1 | Compositions, formulations and kit with anti-sense oligonucleotide and anti-inflammatory steroid and/or obiquinone for treatment of respiratory and lung disesase | EPIGENESIS PHARMACEUTICALS, LLC | 2007-01-25 | — | — | US | claimed |
| US-4041055-A | SULFENYLATION, MICHAEL ADDITION, REACTION WITH THIOPHILE, HYDROLYSIS | THE UPJOHN COMPANY (US) | 1977-08-09 | — | — | US | claimed |
| CN-116637177-A | Combination therapy of prednisone and uricase molecules and uses thereof | 好利恩治疗美国公司 | 2023-08-25 | — | — | CN | disclosed |
| US-20230085022-A1 | COMBINATION THERAPIES OF PREDNISONE AND URICASE MOLECULES AND USES THEREOF | HORIZON THERAPEUTICS USA, INC. | 2023-03-16 | — | — | US | disclosed |
| US-20070021360-A1 | Compositions, formulations and kit with anti-sense oligonucleotide and anti-inflammatory steroid and/or obiquinone for treatment of respiratory and lung disesase | EPIGENESIS PHARMACEUTICALS, LLC | 2007-01-25 | — | — | US | disclosed |
| US-3984544-A | Retinoic acid esters of steroids of the pregnane series, their use in the treatment of acne and pharmaceutical formulations useful therefor | SCHERING CORPORATION (US) | 1976-10-05 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070021360-A1 | Compositions, formulations and kit with anti-sense oligonucleotide and anti-inflammatory steroid and/or obiquinone for treatment of respiratory and lung disesase | RECQL, GSS, DDX17 | NR3C1 104/4885HSD17B10 3010/4885HIF1A 1076/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.